医学
多丽丝(腹足类)
工作队
任务(项目管理)
公共行政
政治学
病毒学
经济
管理
作者
Ronald van Vollenhoven,George Βertsias,Andrea Doria,David Isenberg,Eric F. Morand,Michelle Petri,Bernardo A. Pons‐Estel,Anisur Rahman,Manuel F. Ugarte‐Gil,Alexandre E. Voskuyl,Laurent Arnaud,Ian N Bruce,Ricard Cervera,N. Costedoat‐Chalumeau,Caroline Gordon,Frédéric Houssiau,Marta Mosca,M. Schneider,Michael M. Ward,Graciela S. Alarcón
标识
DOI:10.1136/lupus-2021-000538
摘要
Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator’s Global Assessment <0.5 (0–3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI